1. Home
  2. NAAS vs SCYX Comparison

NAAS vs SCYX Comparison

Compare NAAS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NaaS Technology Inc.

NAAS

NaaS Technology Inc.

HOLD

Current Price

$3.14

Market Cap

41.7M

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.76

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAAS
SCYX
Founded
2019
1999
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.7M
42.4M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
NAAS
SCYX
Price
$3.14
$3.76
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
23.7K
78.7K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.80
$0.57
52 Week High
$4.54
$5.62

Technical Indicators

Market Signals
Indicator
NAAS
SCYX
Relative Strength Index (RSI) 47.95 43.82
Support Level $2.85 $3.68
Resistance Level $3.25 $5.10
Average True Range (ATR) 0.25 0.37
MACD -0.04 -0.16
Stochastic Oscillator 18.19 3.18

Price Performance

Historical Comparison
NAAS
SCYX

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: